Focusing on novel modalities and technology advancement, DualityBio has established a variety of antibody drug conjugate platforms and a robust pipeline targeting oncology and autoimmune diseases. At DualityBio, with our proprietary ADC platforms, we are open to collaborate with external partners on multiple fronts, from target identification, drug discovery, co-development to in- and out-licensing of specific assets. We firmly believe the synergy created through collaboration would propel the innovation and business to the higher level.
If you are interested in exploring business opportunities with us, please send your request to BD contact: email@example.com
DualityBio aims to have a transparent, responsive and flexible approach to work with potential partners to advance its ADC technology and pipeline.
Our current partnering scope includes:
1) Co-develop or partner ex-China rights of Duality’s portfolio with biopharma companies with leading drug development capabilities.
2) ADC Platform collaboration on a target basis with biopharma companies with proprietary antibodies or targets.
3) Partner with IO or other synergistic MoA for combination use with Duality’s ADC products.
4) Innovative partnership models to advance oncology/autoimmune ADCs.